Immunology biotech Acelyrin announced Wednesday morning that its experimental thyroid eye disease treatment improved symptoms in a small handful of patients as part of an early-stage clinical trial.
The drug, though in early development, could one day compete with Tepezza, which in 2020 became the first medicine…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
